- Home
- UMC vs GMAB Comparison
UMC vs GMAB Comparison
Compare UMC & GMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UMC
- GMAB
- Stock Information
- Founded
- UMC 1980
- GMAB 1999
- Country
- UMC Taiwan
- GMAB Denmark
- Employees
- UMC N/A
- GMAB N/A
- Industry
- UMC Semiconductors
- GMAB Biotechnology: Pharmaceutical Preparations
- Sector
- UMC Technology
- GMAB Health Care
- Exchange
- UMC Nasdaq
- GMAB Nasdaq
- Market Cap
- UMC 18.0B
- GMAB 17.4B
- IPO Year
- UMC 2000
- GMAB N/A
- Fundamental
- Price
- UMC $7.17
- GMAB $30.42
- Analyst Decision
- UMC Strong Sell
- GMAB Strong Buy
- Analyst Count
- UMC 1
- GMAB 6
- Target Price
- UMC N/A
- GMAB $40.40
- AVG Volume (30 Days)
- UMC 8.0M
- GMAB 2.4M
- Earning Date
- UMC 10-29-2025
- GMAB 11-06-2025
- Dividend Yield
- UMC 5.20%
- GMAB N/A
- EPS Growth
- UMC N/A
- GMAB 132.41
- EPS
- UMC 0.10
- GMAB 25.10
- Revenue
- UMC $7,746,022,974.00
- GMAB $3,845,670,022.00
- Revenue This Year
- UMC $2.89
- GMAB $24.92
- Revenue Next Year
- UMC $6.57
- GMAB $15.97
- P/E Ratio
- UMC $13.53
- GMAB $1.21
- Revenue Growth
- UMC 4.08
- GMAB 29.57
- 52 Week Low
- UMC $5.61
- GMAB $17.24
- 52 Week High
- UMC $8.33
- GMAB $33.65
- Technical
- Relative Strength Index (RSI)
- UMC 42.89
- GMAB 56.40
- Support Level
- UMC $7.15
- GMAB $28.08
- Resistance Level
- UMC $7.45
- GMAB $30.78
- Average True Range (ATR)
- UMC 0.20
- GMAB 0.68
- MACD
- UMC -0.06
- GMAB 0.10
- Stochastic Oscillator
- UMC 12.57
- GMAB 84.63
About UMC United Microelectronics Corporation (NEW)
Founded in 1980, United Microelectronics is the world's third-largest dedicated chip foundry, with 5% market share in 2024 after TSMC and SMIC. UMC's headquarters are in Hsinchu, Taiwan, and it operates 12 fabs in Taiwan, Mainland China, Japan and Singapore, with additional sales offices in Europe, the us, and South Korea. UMC features a diverse customer base that includes Texas Instruments, MediaTek, Qualcomm, Broadcom, Xilinx, and Realtek, supplying a wide range of products applied in communications, display, memory, automotive and more. UMC employs about 20,000 people.
About GMAB Genmab A/S ADS
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.